AAAAAA

   
Results: 1-8 |
Results: 8
CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: A randomised multicenter study of Southern Italy Cooperative Group
Authors: Lorusso, V Palmieri, G Bianco, AR Abate, G Catalano, G De Vita, F Dammacco, F Lauta, VM Lucarelli, G Polimeno, G Mantovani, G D'Aprile, M Marzullo, F De Lena, M
Citation: V. Lorusso et al., CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: A randomised multicenter study of Southern Italy Cooperative Group, INT J ONCOL, 16(1), 2000, pp. 149-154
Pharmacological elements in clinical application of synthetic peptides
Authors: Lauta, VM
Citation: Vm. Lauta, Pharmacological elements in clinical application of synthetic peptides, FUN CL PHAR, 14(5), 2000, pp. 425-442
Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma
Authors: Zinzani, PL Magagnoli, M Moretti, L De Renzo, A Battista, R Zaccaria, A Guardigni, L Mazza, P Marra, R Ronconi, F Lauta, VM Bendandi, M Gherlinzoni, F Gentilini, P Ciccone, F Cellini, C Stefoni, V Ricciuti, F Gobbi, M Tura, S
Citation: Pl. Zinzani et al., Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma, J CL ONCOL, 18(4), 2000, pp. 773-779
Erythrocytes stored in CPD SAG-mannitol: evaluation of their deformability
Authors: Izzo, P Manicone, A Spagnuolo, A Lauta, VM Di Pasquale, A Di Monte, D
Citation: P. Izzo et al., Erythrocytes stored in CPD SAG-mannitol: evaluation of their deformability, CL HEMORH M, 21(3-4), 1999, pp. 335-339
Reduced deformability of erythrocytes as feature of congenital dyserythropoietic anaemia type II (HEMPAS)
Authors: Izzo, P Spagnuolo, A Manicone, A Nazzaro, P Lauta, VM
Citation: P. Izzo et al., Reduced deformability of erythrocytes as feature of congenital dyserythropoietic anaemia type II (HEMPAS), CL HEMORH M, 21(3-4), 1999, pp. 425-430
How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens fare in the long-term?
Authors: Zinzani, PL Martelli, M Magagnoli, M Zaja, F Storti, S Pavone, E Lauta, VM De Renzo, A Gobbi, M Bocchia, M Ronconi, F Scaramucci, L Gherlinzoni, F Palombi, F Bendandi, M Stefoni, V Borza, PA Cellini, C Mandelli, F Tura, S
Citation: Pl. Zinzani et al., How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens fare in the long-term?, HAEMATOLOG, 84(11), 1999, pp. 996-1001
An analysis of which subgroups of multiple myeloma patients, divided according to beta(2)-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy
Authors: Boccadoro, M Tarella, C Palumbo, A Argentino, C Triolo, S Dominietto, A Callea, V Lauta, VM Molica, S Musto, P Marmont, F Gianni, AM Pileri, A
Citation: M. Boccadoro et al., An analysis of which subgroups of multiple myeloma patients, divided according to beta(2)-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy, HAEMATOLOG, 84(10), 1999, pp. 905-910
Elderly aggressive-histology non-Hodgkin's lymphoma: First-line VNCOP-B regimen experience on 350 patients
Authors: Zinzani, PL Storti, S Zaccaria, A Moretti, L Magagnoli, M Pavone, E Gentilini, P Guardigni, L Gobbi, M Fattori, PP Falini, B Lauta, VM Bendandi, M Gherlinzoni, F De Renzo, A Zaja, F Mazza, P Volpe, E Bocchia, M Aitini, E Tabanelli, M Leone, G Tura, S
Citation: Pl. Zinzani et al., Elderly aggressive-histology non-Hodgkin's lymphoma: First-line VNCOP-B regimen experience on 350 patients, BLOOD, 94(1), 1999, pp. 33-38
Risultati: 1-8 |